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panded CD425 cells prevent BM graft rejection in sublethally
irradiated recipients via a TGF	-independent mechanism. Hanash
and Levy have shown that the addition of donor CD425 cells
resulted in greater lineage committed and multi-potential donor
progenitors in recipient spleens one week post-transplant and sig-
niﬁcantly increased long-term multi-lineage donor chimerism in
sublethally irradiated recipients. A major limitation for the clinical
application of human CD4CD25 cells has been their paucity in
peripheral blood. Only the CD425bright cells are potent sup-
pressors and such cells typically are hypoproliferative. Although
exogenous IL-2 can support human CD4CD25 cell prolifera-
tion the initial protocols published for human CD4CD25 T
cells resulted in limited expansion. However, recent publications
have solved this problem. Studies by Godfrey et al have used a
non-cell sorter, bead-based approach to isolate CD425hi cells
from adult peripheral blood mononuclear cells that were able to be
expanded 100-fold in 2-3 weeks. These expanded CD425
cells were far more potent suppressors of MLR cultures than fresh
cells and retained the expression of L-selhi and other LN homing
receptors. Hoffmann et al have shown that CD425bright cells
can be isolated using cell sorting approaches and that such isolated
cells can be expanded in great numbers while still retaining expres-
sion of L-selhi. Recent studies by Godfrey et al have shown that
cord blood cell CD425 cells are more readily isolated and more
often lead to high levels of suppression as compared to adult
peripheral blood mononuclear cells. These preliminary ﬁndings
demonstrating a high degree of MLR suppression now have been
extended in subsequent studies using 100 cord blood lines gen-
erated to date (B. Blazar and S. Porter, unpublished data). Thus,
the stage is set for clinical trials of CD425 cells for GVHD
inhibition and therapy and engraftment promotion.
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TRANSPLANTATION OF EX VIVO EXPANDED CORD BLOOD
Shpall, E.J.1, de Lima, M.1, McMannis, J.D.1, Robinson, S.1, McNiece,
I.K.2, Champlin, R.E.1 1. The M.D. Anderson Bone Marrow Trans-
plant Department, Houston, TX; 2. Johns Hopkins Oncology Center,
Baltimore, MD
Umbilical cord blood (CB) from unrelated donors is increasingly
used to restore hematopoiesis after myeloablative or more recently,
nonmyeloablative therapy. CB transplants are associated with
higher rates of delayed and failed engraftment than are bone
marrow transplants, particularly for adult patients. At the Univer-
sity of Colorado, we studied the ex vivo expansion of CB in an
attempt to improve time to engraftment and reduce the graft
failure rate in the recipients. In the study, 43 patients with hema-
tologic malignancies (n  40) or breast cancer (n  3) received
high-dose therapy followed by unrelated allogeneic CB transplan-
tation. A fraction of each patient’s CB allograft was CD34-selected
and cultured ex vivo for 10 or 14 days prior to transplantation in
deﬁned media with stem cell factor (SCF), granulocyte colony-
stimulating factor (G-CSF), and megakaryocyte growth and dif-
ferentiation factor (MGDF). The remainder of the CB graft was
infused without further manipulation. Two sequential cohorts of
patients were accrued to the study. The ﬁrst cohort had 40% and
the second cohort had 60% of their CB graft expanded. This study
demonstrated that the CD34 selection and ex vivo expansion of CB
prior to transplantation is feasible. The engraftment failure rate
was relatively low, and the time to neutrophil engraftment in large
adults was in the range reported for pediatric recipients of much
larger CB cell doses. In the successor cord expansion trial being
conducted at the MD Anderson Cancer Center, several changes in
the approach have been made. Patients with hematologic malig-
nancies are now being randomized to receive either two unma-
nipulated CB units or one unmanipulated unit and one unit from
which all the cells are expanded ex vivo. For the patients random-
ized to expansion, on day 
14 one of their cord units is CD133-
selected using the CliniMACS device. The CD133-negative frac-
tion containing the T cells is frozen and the CD133 fraction is
cultured ex vivo for 14 days in media containing SCF, G-CSF and
thrombopoietin (TPO). Following administration of the prepara-
tive regimen, on Day 0, the second unmanipulated CB unit is
infused, followed by the thawed CD133-negative fraction and
ﬁnally, the fraction which has been in culture for two weeks. This
trial was recently initiated and accrual is in progress. Another
expansion trial technology involves the use of a copper chelating
agent, which has been shown by Peled et al to enhance the expan-
sion of a more primitive CD34 CB population when combined
with early acting growth factors. A clinical trial employing this
technology is in progress at MD Anderson. Patients with hemato-
logic malignancies undergoing CB transplantation, with a unit that
is cryopreserved in two fractions are eligible for the study. Twenty
one days prior to infusion, the CD133 cells are isolated from the
smaller cord fraction using the CliniMACS device and cultured for
three weeks in media containing interleukin-6 TPO, FLT-3, SCF,
and the copper chelator tetraethylenepentamine (TEPA). The pa-
tients then receive high-dose therapy with the infusion of the
larger, unmanipulated CB fraction on day 0, and infusion of the
smaller expanded fraction of day 1. Thus far 10 patients have
been enrolled on the study. Evaluable patients engrafted neutro-
phils a median of 27 (range 16-46) in and platelets in a median of
52 (range 27-105) days. An alternative approach for ex vivo expan-
sion is the co-culture of CB cells with bone marrow mesenchymal
stem cells (MSCs) which provide a microenvironment for the
complex molecular cues that direct self-renewal/proliferation and
regulate the differentiation and maturation of hematopoietic prog-
eny. McNiece et al have reported impressive expansion of CB on
MSC stroma. Robinson et al have shown superior expansion of CB
in MSC co-cultures when compared to liquid cultures of the same
CD133 CB fractions. Infusion of MSCs has been shown to
promote engraftment of human CD34 cells in NOD/SCID mice
and fetal sheep. Importantly MSC have been shown to have im-
munomodulatory activity which may reduce graft versus host dis-
ease and enhance engraftment in patients. Clinical evaluation of
CB expansion on MSCs is planned. The pre-clinical data support-
ing this approach as well as updates on the two clinical CB expan-
sion trials described above will be presented at the Los Angeles
meeting.
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IN VIVO STEM CELL FACTOR (R-METHUSCF) AND FILGRASTIM ADMIN-
ISTRATION AFTER UNRELATED UCB TRANSPLANTATION IN ADULTS
Laughlin, M.J. Department of Medicine and Pathology, Case Western
Reserve University, School of Medicine, Cleveland, OH
Allogeneic transplantation with HLA-mismatched unrelated
Umbilical Cord Blood (UCB) is marked by delayed hematologic
recovery when compared with conventional allogeneic graft
sources. UCB graft cell dose correlates with time to myeloid
recovery. Clinical studies have been conducted to improve UCB
graft cell dose including short-term ex vivo expansion, or infusion
of more than one UCB graft. This report summarizes transplant
outcomes for two adults with chronic myelogenous leukemia
(CML), who received myeloablative conditioning followed by in-
fusion of a non-expanded single UCB graft containing a low
mononuclear cell dose. These CML patients were enrolled in a
supportive care clinical transplant trial incorporating in vivo ad-
ministration of recombinant human stem cell factor (R-
MetHuSCF) and ﬁlgrastim administered concomitantly from day
of UCB infusion to time of donor-derived hematopoietic recovery.
Each patient engrafted promptly, with days to donor-derived ab-
solute neutrophil count (ANC) 500/L being 13 and 29 days
respectively. No adverse events attributable to R-MetHuSCF in-
jections were observed. ’In vivo UCB expansion’ with administra-
tion of concomitant R-MetHuSCF and ﬁlgrastim may facilitate
prompt donor hematologic engraftment in adult UCB transplant
recipients.
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AN ALGORITHM FOR SELECTION OF STEM CELL PRODUCTS FOR
TRANSPLANTATION
Barker, J.N. Memorial Sloan-Kettering Cancer Center, New York, NY
To date no prospective randomized studies of unrelated volun-
teer donor bone marrow transplantation (BMT) versus umbilical
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cord blood (UCB) transplantation (UCBT) have been conducted
and therefore how to choose between these alternative stem cell
sources is not known. Encouraging results of 60% long term
disease-free survival (DFS) or better have been achieved using
unrelated volunteer donors in highly selected patient groups such
as young patients with chronic myelogenous leukemia (CML) who
are transplanted early in their disease course using a 6/6 HLA-
matched donor. However, HLA-mismatch, poor disease risk, older
adult age and non-CML diagnosis are associated with a signiﬁ-
cantly worse outcome after unrelated BMT. Further, recently the
importance of matching for HLA class I as well as class II alleles
has been recognized. However, while matching at 8/8 HLA-A, B,
C and DRB1 (or 10/10 if DQ is included) is associated with
improved outcome, this strategy also reduces the “suitable” donor
pool and can potentially prolong the donor search. The 2002 GAO
report to Congress noted that despite considerable efforts on the
part of the National Marrow Donor Program (NMDP) the num-
ber of transplants facilitated by the NMDP “represent about one
tenth of those we estimate to be in need of unrelated donor
transplants”. As an alternative, UCB offers the potential to extend
the donor pool. However, UCB is limited by cell dose and HLA
match. For example, in a collaborative study led by the New York
Blood Center (NYBC), pediatric recipients of 6/6 UCB units had
a comparable and possibly improved outcome compared to
matched BM, and a comparable outcome if they received 5/6 UCB
units of at least 2.5  107 nucleated cells/kilogram (NC/kg).
Inferior outcome was associated with 5/6 units 2.5  107 NC/kg
or 4/6 units. Notably, in the 4/6 setting, high cell dose could at
least partially compensate for mismatch. Further NYBC analysis of
the outcome of US patients transplanted with myeloablative con-
ditioning and single units has demonstrated that a cell dose2.5
107 NC/kg is required in recipients of 5/6 units (bidirectional
mismatch) to achieve at least 50% survival at one year whereas in
4/6 recipients the cell dose needs to be at least 5  107 NC/kg to
achieve similar outcome. Therefore, not surprisingly, studies of
adult single unit UCBT which have involved 4-5/6 matched units
with a median cell dose of less than 2.5 have demonstrated poor
survival. However, the fact that adult UCBT has had a comparable
outcome to mismatched BM introduces UCB as a valid alternative
to mismatched BMT and calls for new strategies to improve adult
UCBT outcome. One possible strategy is double unit grafts which
have been associated with a 2-year DFS of 60% in 31 patients at
the University of Minnesota. This improved outcome is even
despite the low cell dose of the engrafting unit suggesting intrigu-
ing biology of this approach. Overall the minimum acceptable
criteria for both volunteer donor and UCB grafts have not been
deﬁned. Currently it is reasonable that all patients undergo a
volunteer and UCB search at referral. Donor choice will depend on
the patient diagnosis, the urgency of the transplant, the relative
availability of an adequately matched volunteer versus a UCB unit
of adequate dose and match, physician preference and research
priorities. A volunteer donor may be preferred for a patient with
CML in chronic phase or early accelerated phase and possibly for
other diagnoses such as myeloﬁbrosis or severe aplastic anemia. If
the transplant is urgent (required in less than 6 weeks) UCB has a
clear advantage although a volunteer donor could possibly be
obtained using the NMDP ultra fast search strategy. Acceptable
donors include readily available volunteers that are 7-8/8 matched
(or 9-10/10) and 5-6/6 UCBs 2.5  107 NC/kg or 4/6 5  107
NC/kg. Notably, given the interaction of HLA match and cell
dose, a better UCB unit may be smaller but better matched. If
selected volunteers become unavailable during the search then it is
appropriate to default to UCB to prevent an excessively long
search. In UCB selection issues other than HLA match and dose
are also important. It is ideal to perform conﬁrmatory typing from
an attached segment and given CD34 measurements are not
standardized they should not be used unless two units of similar
match and NC dose are available. Markers for infectious diseases
need to be complete and negative with bacterial and fungal culture
negative at freeze. In the future, greater information concerning
the factors determining outcome after volunteer donor and UCB
transplantation may guide more detailed algorithms for donor
selection.
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AUGMENTATION OF HOMING OF CORD BLOOD STEM CELLS
Broxmeyer H.E., Christopherson II K.W., Hangoc G., Campbell T.B.
Department of Microbiology and Immunology and the Walther Oncology
Center, Indiana University School of Medicine, Indianapolis, IN; Insti-
tute of Molecular Medicine for the Prevention of Human Diseases,
University of Texas Health Science Center, Houston, TX
The ﬁeld of cord blood (CB) transplantation has come quite a
way since its inception and the ﬁrst clinical transplant in October
1988. CB hematopoietic stem (HSC) and progenitor (HPC) cells
have been used to treat a wide variety of genetic disorders and
malignancies. These transplants were possible because the cells
could be cryopreserved for prolonged periods of time and stored in
CB banks for future use. The vast majority of CB transplants have
been performed in children and low weight recipients. Fewer CB
transplants have been done in adults and higher weight individuals
because of the limiting numbers of CB cells that are available for
collection and storage at the birth of babies. A number of proce-
dures have been and are being investigated to enhance the efﬁ-
ciency of CB transplantation for adults. This includes attempts at
ex-vivo expansion of HSC, which has not yet provided a clinical
breakthrough because we don’t know enough of the biology re-
garding stem cell self-renewal and proliferation to truly expand the
HSC. Transplantation of multiple CB units is ongoing with early
clinical success, but this procedure has apparently not greatly
reduced the time to engraftment and only one of the transplanted
CB units seems to survive for longer term engraftment. Not all
mouse HSC home with absolute efﬁciency, effects consistent with
clinical experience in which limiting numbers of cells result in graft
failure. The chemokine stromal cell derived factor-1 (SDF-1)/
CXCL12 and its G protein–linked seven transmembrane span-
ning receptor CXCR4 are involved in chemotaxis, mobilization
and homing of HSC and HSC. CD26 is a cell surface dipepti-
dylpeptidase IV, which can truncate SDF-1/CXCL12. We found
that inhibition or deletion of CD26 on target populations contain-
ing or highly enriched for human CB and human and murine bone
marrow HSC/HPC greatly enhanced the chemotactic responsive-
ness of these cells to SDF-1/CXCL12. Inhibition/deletion of
CD26 in mice was associated with greatly decreased ability to
mobilize HPC with G-CSF. Based on these ﬁnds we hypothesized
that enhancement in homing of HSC to the bone marrow niche
needed for support of the self-renewal and proliferative capacity of
HSC would lead to increased engraftment with limiting numbers
of HSC. We tested this hypothesis, ﬁrst with mouse bone marrow
cells transplanted into lethally irradiated congenic mice in the
setting of non-competitive and also competitive repopulation, each
followed by repopulation in a non-competitive repopulation assay
in lethally irradiated secondary congenic mice. Mouse bone mar-
row donor cells pretreated with CD26 inhibitors Diprotin A (Ile-
Pro-Ile) or Val-Pyr or from CD26 gene knock-out (
/
) mice had
greatly enhanced capacity to home to the bone marrow of recipi-
ents, and this was associated with enhanced engraftment, especially
with dose-limiting numbers of donor cells. Recent work from our
laboratory has found that in vitro inhibition of CD26 on human
CD34 CB cells enhances engraftment of these cells in sublethally
irradiated NOD/SCID mice. These encouraging results with CB
cells suggest that targeting CD26, or other means to enhance
homing/engraftment may be of practical value in a clinical setting
to use limiting numbers of CB HSC for successful transplantation.
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STANDARDIZATION OF CORD BLOOD BANKING PROCEDURES NMDP
NETWORK
Kurtzberg, J., Chell, J., Boo, M., Halet, M., Welte, K. The NMDP
Cord Blood Committee
The National Marrow Donor Program established a cord blood
banking program in 1999. Currently, 14 U.S. banks have joined the
network. A steering committee comprised of bank directors, lab-
oratory supervisors, ethicists, obstetricians, scientists, transplanters
and experts in information technology and regulatory affairs and ad
hoc representation from HRSA and the Navy was established and
meets on a quarterly basis. The purpose of the committee is to
advance cord blood transplantation, improve clinical practice and
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